Fortress生物科技 FBIO 深 滬
已收盤 10-10 16:00:00 美东时间
2.71
-0.090
-3.21%
華盛通- 最 高2.8299
- 今 開2.81
- 成交量 76.89万股
- 最 低 2.70
- 昨 收 2.80
- 總市值 8063.55万
- 52周最高 4.20
- 市盈率 靜 --
- 換手率 2.58%
- 52周最低 1.325
- 委 比 41.54%
- 總股本 2975.48万
- 歷史最高 190.50
- 量 比 0.82
- 振 幅 4.64%
- 歷史最低 1.325
- 每 手 1
- 風險率 0.38%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Fortress Biotech plunges as FDA rejects rare disease drug
Fortress Biotech (NASDAQ:FBIO) fell ~31% in the premarket on Wednesday after the U.S. Food and Drug Administration (FDA) declined to approve CUTX-101, a treatment developed by the company and its Indi...
10-01 20:59
Why Ryvyl Shares Are Trading Higher By 97%; Here Are 20 Stocks Moving Premarket
Shares of Ryvyl Inc (NASDAQ:RVYL) rose sharply in pre-market trading after the ...
10-01 17:45
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $205 Million Series A Financing
Urica Therapeutics has sold dotinurad to Crystalys Therapeutics for equity and a 3% royalty. Crystalys secured $205 million in Series A financing to advance global Phase 3 trials for gout. Dotinurad, a next-gen URAT1 inhibitor, has shown strong efficacy and safety, approved in Japan, China, Philippines, and Thailand. This transaction enhances Fortress Biotech's asset value and supports dotinurad's potential approval in the U.S. and Europe.
10-01 12:05
Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101
Fortress Biotech, Inc. and its subsidiary Cyprium Therapeutics announced that the FDA issued a Complete Response Letter (CRL) for CUTX-101's NDA to treat Menkes disease. Sentynl Therapeutics, now responsible for CUTX-101's development, plans to address FDA concerns and resubmit the application. The CRL cited manufacturing deficiencies but no efficacy or safety issues. CUTX-101 holds significant promise for improving survival in Menkes disease, wi...
10-01 12:00
Why Docusign Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
Shares of Docusign Inc (NASDAQ:DOCU) rose sharply in pre-market trading after t...
09-05 17:20
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers iSpecimen (NASDAQ:ISPC) shares rose 52.4% to $1.0 during Thursday's af...
09-05 05:13
Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Fortress Biotech, Inc. announced that Lindsay A. Rosenwald, M.D., its Chairman, President, and CEO, will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference on September 5, 2025. The presentation will be available on-demand for attendees starting at 7:00 a.m. ET and the company will also participate in virtual one-on-one meetings from September 8-11, 2025. Fortress Biotech is an innovative biopharmaceutica...
09-02 12:30
Fortress Biotech shares are trading higher after the company reported better-than-expected Q2 sales results.
Fortress Biotech shares are trading higher after the company reported better-th...
08-16 00:36
Fortress Biotech Q2 EPS $0.45 Beats $(0.36) Estimate, Sales $16.413M Beat $14.534M Estimate
Fortress Biotech (NASDAQ:FBIO) reported quarterly earnings of $0.45 per share which beat the analyst consensus estimate of $(0.36) by 225 percent. This is a 161.64 percent increase over losses of $(0.73) per share from
08-15 04:27
AstraZeneca’s Anselamimab Trial Shows Mixed Results
Fortress Biotech ( ($FBIO) ) has shared an update. On July 16, 2025, AstraZenec...
07-17 05:48
